{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:11:58Z","timestamp":1794543118478,"version":"4.9.1"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41581-025-00934-5","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T13:33:06Z","timestamp":1739280786000},"page":"314-329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["Advances and challenges in kidney fibrosis therapeutics"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6548-6935","authenticated-orcid":false,"given":"Lilia","family":"Abbad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3656-8557","authenticated-orcid":false,"given":"Emmanuel","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4440-099X","authenticated-orcid":false,"given":"Christos","family":"Chatziantoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"934_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong, K. L. et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203\u2013234 (2023).","journal-title":"Lancet"},{"key":"934_CR2","doi-asserted-by":"publisher","first-page":"100438","DOI":"10.1016\/j.lanepe.2022.100438","volume":"20","author":"J Sundstr\u00f6m","year":"2022","unstructured":"Sundstr\u00f6m, J. et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2\u00b74 million patients from 11 countries: the CaReMe CKD study. Lancet Reg. Health Eur. 20, 100438 (2022).","journal-title":"Lancet Reg. Health Eur."},{"key":"934_CR3","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1161\/01.CIR.100.18.1901","volume":"100","author":"JJ Boffa","year":"1999","unstructured":"Boffa, J. J. et al. Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism. Circulation 100, 1901\u20131908 (1999).","journal-title":"Circulation"},{"key":"934_CR4","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0016-5085(00)70370-2","volume":"118","author":"JJ Cho","year":"2000","unstructured":"Cho, J. J. et al. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 118, 1169\u20131178 (2000).","journal-title":"Gastroenterology"},{"key":"934_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41581-022-00590-z","volume":"18","author":"L Li","year":"2022","unstructured":"Li, L., Fu, H. & Liu, Y. The fibrogenic niche in kidney fibrosis: components and mechanisms. Nat. Rev. Nephrol. 18, 545\u2013557 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"934_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/path.4104","volume":"229","author":"F Klingberg","year":"2013","unstructured":"Klingberg, F., Hinz, B. & White, E. S. The myofibroblast matrix: implications for tissue repair and fibrosis. J. Pathol. 229, 298\u2013309 (2013).","journal-title":"J. Pathol."},{"key":"934_CR7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/s41581-023-00752-7","volume":"19","author":"S Tanaka","year":"2023","unstructured":"Tanaka, S., Portilla, D. & Okusa, M. D. Role of perivascular cells in kidney homeostasis, inflammation, repair and fibrosis. Nat. Rev. Nephrol. 19, 721\u2013732 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"934_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","volume":"8","author":"R Huang","year":"2023","unstructured":"Huang, R., Fu, P. & Ma, L. Kidney fibrosis: from mechanisms to therapeutic medicines. Signal. Transduct. Target. Ther. 8, 1\u201320 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"934_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41586-020-2941-1","volume":"589","author":"C Kuppe","year":"2021","unstructured":"Kuppe, C. et al. Decoding myofibroblast origins in human kidney fibrosis. Nature 589, 281\u2013286 (2021).","journal-title":"Nature"},{"key":"934_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44886-z","volume":"15","author":"C Cohen","year":"2024","unstructured":"Cohen, C. et al. WNT-dependent interaction between inflammatory fibroblasts and FOLR2+ macrophages promotes fibrosis in chronic kidney disease. Nat. Commun. 15, 743 (2024).","journal-title":"Nat. Commun."},{"key":"934_CR11","doi-asserted-by":"publisher","first-page":"F261","DOI":"10.1152\/ajprenal.00263.2006","volume":"292","author":"L Wu","year":"2007","unstructured":"Wu, L. et al. Peritubular capillary dysfunction and renal tubular epithelial cell stress following lipopolysaccharide administration in mice. Am. J. Physiol. Renal Physiol. 292, F261\u2013F268 (2007).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"934_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000365149","volume":"51","author":"C Schrimpf","year":"2014","unstructured":"Schrimpf, C., Teebken, O. E., Wilhelmi, M. & Duffield, J. S. The role of pericyte detachment in vascular rarefaction. J. Vasc. Res. 51, 247\u2013258 (2014).","journal-title":"J. Vasc. Res."},{"key":"934_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nrneph.2015.3","volume":"11","author":"DA Ferenbach","year":"2015","unstructured":"Ferenbach, D. A. & Bonventre, J. V. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat. Rev. Nephrol. 11, 264\u2013276 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"934_CR14","doi-asserted-by":"publisher","first-page":"101530","DOI":"10.1016\/j.jbc.2021.101530","volume":"298","author":"L Moretti","year":"2022","unstructured":"Moretti, L., Stalfort, J., Barker, T. H. & Abebayehu, D. The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation. J. Biol. Chem. 298, 101530 (2022).","journal-title":"J. Biol. Chem."},{"key":"934_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/cei.13119","volume":"192","author":"J Tecklenborg","year":"2018","unstructured":"Tecklenborg, J., Clayton, D., Siebert, S. & Coley, S. M. The role of the immune system in kidney disease. Clin. Exp. Immunol. 192, 142 (2018).","journal-title":"Clin. Exp. Immunol."},{"key":"934_CR16","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.3390\/jcm9082359","volume":"9","author":"S Roumeliotis","year":"2020","unstructured":"Roumeliotis, S., Mallamaci, F. & Zoccali, C. Endothelial dysfunction in chronic kidney disease, from biology to clinical outcomes: a 2020 update. J. Clin. Med. 9, 2359 (2020).","journal-title":"J. Clin. Med."},{"key":"934_CR17","first-page":"183","volume":"30","author":"Q Cao","year":"2015","unstructured":"Cao, Q., Harris, D. C. H. & Wang, Y. Macrophages in kidney injury, inflammation, and fibrosis. Physiol. Bethesda Md. 30, 183\u2013194 (2015).","journal-title":"Physiol. Bethesda Md."},{"key":"934_CR18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.2353\/ajpath.2008.070726","volume":"172","author":"NC Henderson","year":"2008","unstructured":"Henderson, N. C. et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol. 172, 288\u2013298 (2008).","journal-title":"Am. J. Pathol."},{"key":"934_CR19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI156876","volume":"132","author":"S Ryu","year":"2022","unstructured":"Ryu, S. et al. Siglec-F-expressing neutrophils are essential for creating a profibrotic microenvironment in renal fibrosis. J. Clin. Invest. 132, e156876 (2022).","journal-title":"J. Clin. Invest."},{"key":"934_CR20","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1007\/s10753-014-9941-y","volume":"37","author":"B Shen","year":"2014","unstructured":"Shen, B., Liu, X., Fan, Y. & Qiu, J. Macrophages regulate renal fibrosis through modulating TGF\u03b2 superfamily signaling. Inflammation 37, 2076\u20132084 (2014).","journal-title":"Inflammation"},{"key":"934_CR21","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1164\/ajrccm.161.5.9907065","volume":"161","author":"A Pardo","year":"2000","unstructured":"Pardo, A. et al. Increase of lung neutrophils in hypersensitivity pneumonitis is associated with lung fibrosis. Am. J. Respir. Crit. Care Med. 161, 1698\u20131704 (2000).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"934_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1172\/JCI200522675","volume":"115","author":"JS Duffield","year":"2005","unstructured":"Duffield, J. S. et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest. 115, 56\u201365 (2005).","journal-title":"J. Clin. Invest."},{"key":"934_CR23","doi-asserted-by":"publisher","first-page":"12190","DOI":"10.3390\/ijms222212190","volume":"22","author":"YA Gebru","year":"2021","unstructured":"Gebru, Y. A. et al. T cell subsets and natural killer cells in the pathogenesis of nonalcoholic fatty liver disease. Int. J. Mol. Sci. 22, 12190 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"934_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.34067\/KID.0000000000000305","volume":"5","author":"KG Burfeind","year":"2024","unstructured":"Burfeind, K. G., Funahashi, Y., Munhall, A. C., Eiwaz, M. & Hutchens, M. P. Natural killer lymphocytes mediate renal fibrosis due to acute cardiorenal syndrome. Kidney360 5, 8\u201321 (2024).","journal-title":"Kidney360"},{"key":"934_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.cytogfr.2004.03.006","volume":"15","author":"JC Bonner","year":"2004","unstructured":"Bonner, J. C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 15, 255\u2013273 (2004).","journal-title":"Cytokine Growth Factor Rev."},{"key":"934_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/08977194.2011.595714","volume":"29","author":"A Biernacka","year":"2011","unstructured":"Biernacka, A., Dobaczewski, M. & Frangogiannis, N. G. TGF-\u03b2 signaling in fibrosis. Growth Factors 29, 196\u2013202 (2011).","journal-title":"Growth Factors"},{"key":"934_CR27","doi-asserted-by":"publisher","first-page":"G219","DOI":"10.1152\/ajpgi.00160.2016","volume":"312","author":"L Beljaars","year":"2017","unstructured":"Beljaars, L., Daliri, S., Dijkhuizen, C., Poelstra, K. & Gosens, R. WNT-5A regulates TGF-\u03b2-related activities in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 312, G219\u2013G227 (2017).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"934_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/biom13010119","volume":"13","author":"J Liu","year":"2023","unstructured":"Liu, J., Wang, F. & Luo, F. The role of JAK\/STAT pathway in fibrotic diseases: molecular and cellular mechanisms. Biomolecules 13, 119 (2023).","journal-title":"Biomolecules"},{"key":"934_CR29","doi-asserted-by":"publisher","first-page":"jcs232157","DOI":"10.1242\/jcs.232157","volume":"132","author":"O Contreras","year":"2019","unstructured":"Contreras, O. et al. Cross-talk between TGF-\u03b2 and PDGFR\u03b1 signaling pathways regulates the fate of stromal fibro-adipogenic progenitors. J. Cell Sci. 132, jcs232157 (2019).","journal-title":"J. Cell Sci."},{"key":"934_CR30","first-page":"3907","volume":"18","author":"Y Sun","year":"2018","unstructured":"Sun, Y., Zhang, Y. & Chi, P. Pirfenidone suppresses TGF-\u03b21-induced human intestinal fibroblasts activities by regulating proliferation and apoptosis via the inhibition of the Smad and PI3K\/AKT signaling pathway. Mol. Med. Rep. 18, 3907\u20133913 (2018).","journal-title":"Mol. Med. Rep."},{"key":"934_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.yexmp.2008.08.003","volume":"85","author":"Y Morimoto","year":"2008","unstructured":"Morimoto, Y. et al. TNF-\u0251 deficiency accelerates renal tubular interstitial fibrosis in the late stage of ureteral obstruction. Exp. Mol. Pathol. 85, 207\u2013213 (2008).","journal-title":"Exp. Mol. Pathol."},{"key":"934_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35306-1","volume":"13","author":"AA Widjaja","year":"2022","unstructured":"Widjaja, A. A. et al. Targeting endogenous kidney regeneration using anti-IL11 therapy in acute and chronic models of kidney disease. Nat. Commun. 13, 7497 (2022).","journal-title":"Nat. Commun."},{"key":"934_CR33","doi-asserted-by":"publisher","first-page":"G950","DOI":"10.1152\/ajpgi.00132.2011","volume":"301","author":"TN Wight","year":"2011","unstructured":"Wight, T. N. & Potter-Perigo, S. The extracellular matrix: an active or passive player in fibrosis? Am. J. Physiol. Gastrointest. Liver Physiol. 301, G950\u2013G955 (2011).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"934_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.matbio.2020.04.005","volume":"91\u201392","author":"M AlQudah","year":"2020","unstructured":"AlQudah, M., Hale, T. M. & Czubryt, M. P. Targeting the renin-angiotensin-aldosterone system in fibrosis. Matrix Biol. J. Int. Soc. Matrix Biol. 91\u201392, 92\u2013108 (2020).","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"934_CR35","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1097\/FJC.0000000000001359","volume":"80","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y., Sun, Z., Li, L., Yuan, W. & Wang, Z. Role of collagen in vascular calcification. J. Cardiovasc. Pharmacol. 80, 769\u2013778 (2022).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"934_CR36","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1091\/mbc.E19-03-0140","volume":"30","author":"JT Saunders","year":"2019","unstructured":"Saunders, J. T. & Schwarzbauer, J. E. Fibronectin matrix as a scaffold for procollagen proteinase binding and collagen processing. Mol. Biol. Cell 30, 2218\u20132226 (2019).","journal-title":"Mol. Biol. Cell"},{"key":"934_CR37","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1369\/0022155419849388","volume":"67","author":"RD B\u00fclow","year":"2019","unstructured":"B\u00fclow, R. D. & Boor, P. Extracellular matrix in kidney fibrosis: more than just a scaffold. J. Histochem. Cytochem. 67, 643\u2013661 (2019).","journal-title":"J. Histochem. Cytochem."},{"key":"934_CR38","doi-asserted-by":"publisher","first-page":"F1351","DOI":"10.1152\/ajprenal.00037.2012","volume":"302","author":"RJ Tan","year":"2012","unstructured":"Tan, R. J. & Liu, Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am. J. Physiol. Renal Physiol. 302, F1351\u2013F1361 (2012).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"934_CR39","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2353\/ajpath.2008.080025","volume":"173","author":"N Shweke","year":"2008","unstructured":"Shweke, N. et al. Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-\u03b2 activation and cell infiltration. Am. J. Pathol. 173, 631\u2013642 (2008).","journal-title":"Am. J. Pathol."},{"key":"934_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2165\/11319550-000000000-00000","volume":"24","author":"JJ Swigris","year":"2010","unstructured":"Swigris, J. J. & Brown, K. K. The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis. BioDrugs 24, 49\u201354 (2010).","journal-title":"BioDrugs"},{"key":"934_CR41","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/ki.2014.143","volume":"86","author":"DE Kohan","year":"2014","unstructured":"Kohan, D. E. & Barton, M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 86, 896\u2013904 (2014).","journal-title":"Kidney Int."},{"key":"934_CR42","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1073\/pnas.83.12.4167","volume":"83","author":"AB Roberts","year":"1986","unstructured":"Roberts, A. B. et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl Acad. Sci. USA 83, 4167\u20134171 (1986).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"934_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01668-1","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng, Z. et al. TGF-\u03b2 signaling in health, disease and therapeutics. Signal. Transduct. Target. Ther. 9, 1\u201340 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"934_CR44","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/ndt\/14.5.1078","volume":"14","author":"A Mogyorosi","year":"1999","unstructured":"Mogyorosi, A. What is the role of decorin in diabetic kidney disease? Nephrol. Dial. Transplant. 14, 1078\u20131081 (1999).","journal-title":"Nephrol. Dial. Transplant."},{"key":"934_CR45","first-page":"179","volume":"16","author":"S Klahr","year":"2003","unstructured":"Klahr, S. The bone morphogenetic proteins (BMPs). Their role in renal fibrosis and renal function. J. Nephrol. 16, 179\u2013185 (2003).","journal-title":"J. Nephrol."},{"key":"934_CR46","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ki.2011.33","volume":"79","author":"H Trachtman","year":"2011","unstructured":"Trachtman, H. et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-\u03b2 antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 79, 1236\u20131243 (2011).","journal-title":"Kidney Int."},{"key":"934_CR47","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.ekir.2017.03.011","volume":"2","author":"F Vincenti","year":"2017","unstructured":"Vincenti, F. et al. A phase 2, double-blind, placebo-controlled, randomized study of fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis. Kidney Int. Rep. 2, 800\u2013810 (2017).","journal-title":"Kidney Int. Rep."},{"key":"934_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090353","volume":"9","author":"JC Morris","year":"2014","unstructured":"Morris, J. C. et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE 9, e90353 (2014).","journal-title":"PLoS ONE"},{"key":"934_CR49","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1105351","volume":"365","author":"PE Pergola","year":"2011","unstructured":"Pergola, P. E. et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327\u2013336 (2011).","journal-title":"N. Engl. J. Med."},{"key":"934_CR50","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ekir.2020.03.030","volume":"5","author":"M Nangaku","year":"2020","unstructured":"Nangaku, M. et al. Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI Study). Kidney Int. Rep. 5, 879\u2013890 (2020).","journal-title":"Kidney Int. Rep."},{"key":"934_CR51","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.cardfail.2014.10.001","volume":"20","author":"MP Chin","year":"2014","unstructured":"Chin, M. P. et al. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J. Card. Fail. 20, 953\u2013958 (2014).","journal-title":"J. Card. Fail."},{"key":"934_CR52","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.kint.2019.04.027","volume":"96","author":"P Rossing","year":"2019","unstructured":"Rossing, P. et al. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. Kidney Int. 96, 1030\u20131036 (2019).","journal-title":"Kidney Int."},{"key":"934_CR53","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1681\/ASN.2016121280","volume":"28","author":"MA Baker","year":"2017","unstructured":"Baker, M. A. et al. Tissue-specific MicroRNA expression patterns in four types of kidney disease. J. Am. Soc. Nephrol. 28, 2985 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"934_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47504-x","volume":"9","author":"J Zang","year":"2019","unstructured":"Zang, J., Maxwell, A. P., Simpson, D. A. & McKay, G. J. Differential expression of urinary exosomal microRNAs miR-21-5p and miR-30b-5p in individuals with diabetic kidney disease. Sci. Rep. 9, 10900 (2019).","journal-title":"Sci. Rep."},{"key":"934_CR55","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1083\/jcb.200312172","volume":"165","author":"JP Annes","year":"2004","unstructured":"Annes, J. P., Chen, Y., Munger, J. S. & Rifkin, D. B. Integrin \u03b1V\u03b26-mediated activation of latent TGF-\u03b2 requires the latent TGF-\u03b2 binding protein-1. J. Cell Biol. 165, 723\u2013734 (2004).","journal-title":"J. Cell Biol."},{"key":"934_CR56","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1164\/rccm.202205-0868LE","volume":"206","author":"G Raghu","year":"2022","unstructured":"Raghu, G. et al. Randomized phase IIa clinical study of an anti-\u03b1v\u03b26 monoclonal antibody in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 206, 1166\u20131168 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"934_CR57","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1111\/ajt.12467","volume":"13","author":"DJ Lo","year":"2013","unstructured":"Lo, D. J. et al. Inhibition of \u03b1v\u03b26 promotes acute renal allograft rejection in nonhuman primates. Am. J. Transplant. 13, 3085\u20133093 (2013).","journal-title":"Am. J. Transplant."},{"key":"934_CR58","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00878761 (2011)."},{"key":"934_CR59","first-page":"1010","volume":"18","author":"K Choi","year":"2012","unstructured":"Choi, K. et al. Pirfenidone inhibits transforming growth factor-\u03b21-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19. Mol. Vis. 18, 1010\u20131020 (2012).","journal-title":"Mol. Vis."},{"key":"934_CR60","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.bbrc.2007.01.012","volume":"354","author":"I Burghardt","year":"2007","unstructured":"Burghardt, I. et al. Pirfenidone inhibits TGF-\u03b2 expression in malignant glioma cells. Biochem. Biophys. Res. Commun. 354, 542\u2013547 (2007).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"934_CR61","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3346\/jkms.2003.18.4.527","volume":"18","author":"H-S Park","year":"2003","unstructured":"Park, H.-S. et al. Pirfenidone suppressed the development of glomerulosclerosis in the FGS\/Kist mouse. J. Korean Med. Sci. 18, 527\u2013533 (2003).","journal-title":"J. Korean Med. Sci."},{"key":"934_CR62","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King","year":"2014","unstructured":"King, T. E. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2083\u20132092 (2014).","journal-title":"N. Engl. J. Med."},{"key":"934_CR63","doi-asserted-by":"publisher","first-page":"906","DOI":"10.2215\/CJN.01050207","volume":"2","author":"ME Cho","year":"2007","unstructured":"Cho, M. E., Smith, D. C., Branton, M. H., Penzak, S. R. & Kopp, J. B. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2, 906 (2007).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"934_CR64","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1681\/ASN.2010101049","volume":"22","author":"K Sharma","year":"2011","unstructured":"Sharma, K. et al. Pirfenidone for diabetic nephropathy. J. Am. Soc. Nephrol. 22, 1144\u20131151 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"934_CR65","doi-asserted-by":"publisher","first-page":"170057","DOI":"10.1183\/16000617.0057-2017","volume":"26","author":"LH Lancaster","year":"2017","unstructured":"Lancaster, L. H. et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur. Respir. Rev. 26, 170057 (2017).","journal-title":"Eur. Respir. Rev."},{"key":"934_CR66","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1111\/liv.15715","volume":"43","author":"X Xu","year":"2023","unstructured":"Xu, X. et al. Hydronidone ameliorates liver fibrosis by inhibiting activation of hepatic stellate cells via Smad7-mediated degradation of TGF\u03b2RI. Liver Int. 43, 2523\u20132537 (2023).","journal-title":"Liver Int."},{"key":"934_CR67","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.cgh.2022.05.056","volume":"21","author":"X Cai","year":"2023","unstructured":"Cai, X. et al. Hydronidone for the treatment of liver fibrosis related to chronic hepatitis B: a phase 2 randomized controlled trial. Clin. Gastroenterol. Hepatol. 21, 1893\u20131901.e7 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"934_CR68","doi-asserted-by":"publisher","first-page":"848263","DOI":"10.3389\/fphar.2022.848263","volume":"13","author":"Y Lin","year":"2022","unstructured":"Lin, Y., Xu, Z., Zhou, B., Ma, K. & Jiang, M. Pentoxifylline inhibits pulmonary fibrosis by regulating cellular senescence in mice. Front. Pharmacol. 13, 848263 (2022).","journal-title":"Front. Pharmacol."},{"key":"934_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57850-0","volume":"14","author":"V Demircan","year":"2024","unstructured":"Demircan, V. et al. Evaluation of therapeutic use of a combination of pentoxifylline and vitamin E in radiation-induced renal fibrosis. Sci. Rep. 14, 6977 (2024).","journal-title":"Sci. Rep."},{"key":"934_CR70","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2337\/dc18-0078","volume":"41","author":"JF Navarro-Gonz\u00e1lez","year":"2018","unstructured":"Navarro-Gonz\u00e1lez, J. F. et al. Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease. Diabetes Care 41, 1817\u20131820 (2018).","journal-title":"Diabetes Care"},{"key":"934_CR71","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s13300-022-01250-y","volume":"13","author":"F Moosaie","year":"2022","unstructured":"Moosaie, F. et al. Effects of pentoxifylline on serum markers of diabetic nephropathy in type 2 diabetes. Diabetes Ther. 13, 1023\u20131036 (2022).","journal-title":"Diabetes Ther."},{"key":"934_CR72","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1042\/CS20170134","volume":"131","author":"F Liu","year":"2017","unstructured":"Liu, F. et al. Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease. Clin. Sci. Lond. Engl. 131, 2125\u20132143 (2017).","journal-title":"Clin. Sci. Lond. Engl."},{"key":"934_CR73","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000509670","volume":"7","author":"L Feng","year":"2021","unstructured":"Feng, L. et al. Synergistic inhibition of renal fibrosis by nintedanib and gefitinib in a murine model of obstructive nephropathy. Kidney Dis. 7, 34\u201349 (2021).","journal-title":"Kidney Dis."},{"key":"934_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04248-9","volume":"12","author":"A Jamadar","year":"2021","unstructured":"Jamadar, A. et al. The tyrosine-kinase inhibitor nintedanib ameliorates autosomal-dominant polycystic kidney disease. Cell Death Dis. 12, 947 (2021).","journal-title":"Cell Death Dis."},{"key":"934_CR75","doi-asserted-by":"publisher","first-page":"A1309","DOI":"10.1016\/j.chest.2019.08.1173","volume":"156","author":"M Saint-Pierre","year":"2019","unstructured":"Saint-Pierre, M. Tolerability of nintedanib in severe chronic kidney disease (CKD): a case study. Chest 156, A1309 (2019).","journal-title":"Chest"},{"key":"934_CR76","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13730-020-00474-w","volume":"9","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa, M. et al. Nintedanib-induced glomerular microangiopathy: a case report. Cen. Case Rep. 9, 295\u2013300 (2020).","journal-title":"Cen. Case Rep."},{"key":"934_CR77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5414\/CN109900","volume":"93","author":"D Inoue","year":"2020","unstructured":"Inoue, D. et al. Renal thrombotic microangiopathy during nintedanib treatment for idiopathic pulmonary fibrosis. Clin. Nephrol. 93, 47\u201350 (2020).","journal-title":"Clin. Nephrol."},{"key":"934_CR78","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/MNH.0000000000000079","volume":"24","author":"FC Brosius","year":"2015","unstructured":"Brosius, F. C. & He, J. C. JAK inhibition and progressive kidney disease. Curr. Opin. Nephrol. Hypertens. 24, 88\u201395 (2015).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"934_CR79","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","volume":"18","author":"J Mascarenhas","year":"2012","unstructured":"Mascarenhas, J. & Hoffman, R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin. Cancer Res. 18, 3008\u20133014 (2012).","journal-title":"Clin. Cancer Res."},{"key":"934_CR80","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/17474086.2022.2098105","volume":"15","author":"C Saha","year":"2022","unstructured":"Saha, C. & Harrison, C. Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis \u2014 an option beyond ruxolitinib. Expert. Rev. Hematol. 15, 583\u2013595 (2022).","journal-title":"Expert. Rev. Hematol."},{"key":"934_CR81","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace, D. J. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392, 222\u2013231 (2018).","journal-title":"Lancet"},{"key":"934_CR82","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri, M. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 401, 1011\u20131019 (2023).","journal-title":"Lancet"},{"key":"934_CR83","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","volume":"33","author":"KR Tuttle","year":"2018","unstructured":"Tuttle, K. R. et al. JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial. Nephrol. Dial. Transplant. 33, 1950\u20131959 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"934_CR84","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653\u2013662 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"934_CR85","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12933-023-01829-0","volume":"22","author":"M Schechter","year":"2023","unstructured":"Schechter, M. et al. Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence. Cardiovasc. Diabetol. 22, 126 (2023).","journal-title":"Cardiovasc. Diabetol."},{"key":"934_CR86","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"934_CR87","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","volume":"17","author":"RZ Alicic","year":"2021","unstructured":"Alicic, R. Z., Cox, E. J., Neumiller, J. J. & Tuttle, K. R. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat. Rev. Nephrol. 17, 227\u2013244 (2021).","journal-title":"Nat. Rev. Nephrol."},{"key":"934_CR88","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078242","volume":"385","author":"N Simms-Williams","year":"2024","unstructured":"Simms-Williams, N. et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ 385, e078242 (2024).","journal-title":"BMJ"},{"key":"934_CR89","doi-asserted-by":"publisher","first-page":"ra48","DOI":"10.1126\/scisignal.2004911","volume":"7","author":"H Kalyanaraman","year":"2014","unstructured":"Kalyanaraman, H. et al. Nongenomic thyroid hormone signaling occurs through a plasma membrane-localized receptor. Sci. Signal. 7, ra48\u2013ra48 (2014).","journal-title":"Sci. Signal."},{"key":"934_CR90","doi-asserted-by":"publisher","first-page":"E3451","DOI":"10.1073\/pnas.1506113113","volume":"113","author":"E Alonso-Merino","year":"2016","unstructured":"Alonso-Merino, E. et al. Thyroid hormones inhibit TGF-\u03b2 signaling and attenuate fibrotic responses. Proc. Natl Acad. Sci. USA 113, E3451\u2013E3460 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"934_CR91","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497\u2013509 (2024).","journal-title":"N. Engl. J. Med."},{"key":"934_CR92","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035613","volume":"102","author":"S He","year":"2023","unstructured":"He, S., Yao, L. & Li, J. Role of MCP-1\/CCR2 axis in renal fibrosis: mechanisms and therapeutic targeting. Medicine 102, e35613 (2023).","journal-title":"Medicine"},{"key":"934_CR93","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05183646 (2023)."},{"key":"934_CR94","doi-asserted-by":"publisher","first-page":"109861","DOI":"10.1016\/j.cellsig.2020.109861","volume":"78","author":"C Donati","year":"2021","unstructured":"Donati, C., Cencetti, F., Bernacchioni, C., Vannuzzi, V. & Bruni, P. Role of sphingosine 1-phosphate signalling in tissue fibrosis. Cell. Signal. 78, 109861 (2021).","journal-title":"Cell. Signal."},{"key":"934_CR95","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/(SICI)1096-9896(199903)187:4<481::AID-PATH263>3.0.CO;2-2","volume":"187","author":"S Sasaki","year":"1999","unstructured":"Sasaki, S., Bao, Q. & Hughes, R. C. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J. Pathol. 187, 481\u2013489 (1999).","journal-title":"J. Pathol."},{"key":"934_CR96","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3390\/biomedicines10030585","volume":"10","author":"S-M Ou","year":"2022","unstructured":"Ou, S.-M. et al. Urinary galectin-3 as a novel biomarker for the prediction of renal fibrosis and kidney disease progression. Biomedicines 10, 585 (2022).","journal-title":"Biomedicines"},{"key":"934_CR97","doi-asserted-by":"publisher","first-page":"F500","DOI":"10.1152\/ajprenal.00461.2014","volume":"308","author":"A-RS Frenay","year":"2015","unstructured":"Frenay, A.-R. S. et al. Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. Am. J. Physiol. Renal Physiol. 308, F500\u2013F509 (2015).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"934_CR98","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s00467-006-0016-7","volume":"21","author":"J-W Chien","year":"2006","unstructured":"Chien, J.-W. et al. Daily urinary interleukin-11 excretion correlated with proteinuria in IgA nephropathy and lupus nephritis. Pediatr. Nephrol. 21, 490\u2013496 (2006).","journal-title":"Pediatr. Nephrol."},{"key":"934_CR99","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1007\/s00204-019-02611-6","volume":"93","author":"E Bigaeva","year":"2019","unstructured":"Bigaeva, E. et al. Transcriptomic characterization of culture-associated changes in murine and human precision-cut tissue slices. Arch. Toxicol. 93, 3549\u20133583 (2019).","journal-title":"Arch. Toxicol."},{"key":"934_CR100","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-med-041818-011649","volume":"71","author":"SA Cook","year":"2020","unstructured":"Cook, S. A. & Schafer, S. Hiding in plain sight: interleukin-11 emerges as a master regulator of fibrosis, tissue integrity, and stromal inflammation. Annu. Rev. Med. 71, 263\u2013276 (2020).","journal-title":"Annu. Rev. Med."},{"key":"934_CR101","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/j.ajpath.2023.07.005","volume":"193","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Renal fibrosis is alleviated through targeted inhibition of IL-11-induced renal tubular epithelial-to-mesenchymal transition. Am. J. Pathol. 193, 1936\u20131952 (2023).","journal-title":"Am. J. Pathol."},{"key":"934_CR102","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1681\/ASN.2021040577","volume":"33","author":"AA Widjaja","year":"2022","unstructured":"Widjaja, A. A. et al. A neutralizing IL-11 antibody improves renal function and increases lifespan in a mouse model of Alport syndrome. J. Am. Soc. Nephrol. 33, 718 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"934_CR103","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ajpath.2013.04.020","volume":"183","author":"X Tang","year":"2013","unstructured":"Tang, X. et al. Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis. Am. J. Pathol. 183, 470\u2013479 (2013).","journal-title":"Am. J. Pathol."},{"key":"934_CR104","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1159\/000488257","volume":"43","author":"E Kulikowski","year":"2018","unstructured":"Kulikowski, E. et al. Apabetalone mediated epigenetic modulation is associated with favorable kidney function and alkaline phosphatase profile in patients with chronic kidney disease. Kidney Blood Press. Res. 43, 449\u2013457 (2018).","journal-title":"Kidney Blood Press. Res."},{"key":"934_CR105","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2215\/CJN.16751020","volume":"16","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh, K. et al. Effect of apabetalone on cardiovascular events in diabetes, CKD, and recent acute coronary syndrome: results from the BETonMACE randomized controlled trial. Clin. J. Am. Soc. Nephrol. 16, 705 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"934_CR106","unstructured":"US National Library of Medicine. Clinicaltrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03228940 (2023)."},{"key":"934_CR107","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1681\/ASN.2017020148","volume":"28","author":"AK Cheung","year":"2017","unstructured":"Cheung, A. K. et al. Effects of intensive BP control in CKD. J. Am. Soc. Nephrol. 28, 2812\u20132823 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"934_CR108","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","volume":"80","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3\u20135: a network meta-analysis of randomised clinical trials. Drugs 80, 797\u2013811 (2020).","journal-title":"Drugs"},{"key":"934_CR109","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie, X. et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am. J. Kidney Dis. 67, 728\u2013741 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"934_CR110","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","volume":"385","author":"R Agarwal","year":"2021","unstructured":"Agarwal, R. et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N. Engl. J. Med. 385, 2507\u20132519 (2021).","journal-title":"N. Engl. J. Med."},{"key":"934_CR111","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.kint.2023.09.012","volume":"105","author":"S Bhandari","year":"2024","unstructured":"Bhandari, S. et al. Evaluation of the stopping angiotensin converting enzyme inhibitor compared to angiotensin receptor blocker (STOP ACEi trial) in advanced and progressive chronic kidney disease. Kidney Int. 105, 200\u2013208 (2024).","journal-title":"Kidney Int."},{"key":"934_CR112","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/s41440-022-00877-5","volume":"45","author":"T Nakayama","year":"2022","unstructured":"Nakayama, T. et al. Effects of renin-angiotensin system inhibitors on the incidence of unplanned dialysis. Hypertens. Res. 45, 1018\u20131027 (2022).","journal-title":"Hypertens. Res."},{"key":"934_CR113","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41581-019-0248-y","volume":"16","author":"M Ruiz-Ortega","year":"2020","unstructured":"Ruiz-Ortega, M., Rayego-Mateos, S., Lamas, S., Ortiz, A. & Rodrigues-Diez, R. R. Targeting the progression of chronic kidney disease. Nat. Rev. Nephrol. 16, 269\u2013288 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"934_CR114","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai, A. S. et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N. Engl. J. Med. 389, 228\u2013238 (2023).","journal-title":"N. Engl. J. Med."},{"key":"934_CR115","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jama.2024.0728","volume":"331","author":"GL Bakris","year":"2024","unstructured":"Bakris, G. L. et al. RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial. JAMA 331, 740\u2013749 (2024).","journal-title":"JAMA"},{"key":"934_CR116","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05103332 (2024)."},{"key":"934_CR117","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06272487 (2025)."},{"key":"934_CR118","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","volume":"80","author":"M Epstein","year":"2022","unstructured":"Epstein, M., Kovesdy, C. P., Clase, C. M., Sood, M. M. & Pecoits-Filho, R. Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms. Am. J. Kidney Dis. 80, 658\u2013666 (2022).","journal-title":"Am. J. Kidney Dis."},{"key":"934_CR119","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","volume":"28","author":"K Rossing","year":"2005","unstructured":"Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F. & Parving, H.-H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 28, 2106\u20132112 (2005).","journal-title":"Diabetes Care"},{"key":"934_CR120","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein, M. et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 1, 940 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"934_CR121","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur. Heart J. 43, 474\u2013484 (2022).","journal-title":"Eur. Heart J."},{"key":"934_CR122","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens, P. E. et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117\u2013S314 (2024).","journal-title":"Kidney Int."},{"key":"934_CR123","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1681\/ASN.0000000000000186","volume":"34","author":"Z Zhu","year":"2023","unstructured":"Zhu, Z. et al. Finerenone added to RAS\/SGLT2 blockade for CKD in Alport syndrome. Results of a randomized controlled trial with Col4a3\u2212\/\u2212\u00a0mice. J. Am. Soc. Nephrol. 34, 1513\u20131520 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"934_CR124","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman, M. W. et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N. Engl. J. Med. 388, 395\u2013405 (2023).","journal-title":"N. Engl. J. Med."},{"key":"934_CR125","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.semnephrol.2015.02.004","volume":"35","author":"Z Guan","year":"2015","unstructured":"Guan, Z., VanBeusecum, J. P. & Inscho, E. W. Endothelin and the renal vasculature. Semin. Nephrol. 35, 145\u2013155 (2015).","journal-title":"Semin. Nephrol."},{"key":"934_CR126","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00467-020-04518-2","volume":"36","author":"A Benigni","year":"2021","unstructured":"Benigni, A., Buelli, S. & Kohan, D. E. Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition. Pediatr. Nephrol. 36, 763\u2013775 (2021).","journal-title":"Pediatr. Nephrol."},{"key":"934_CR127","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003896","volume":"5","author":"A Wei","year":"2016","unstructured":"Wei, A. et al. Clinical adverse effects of endothelin receptor antagonists: insights from the meta\u2010analysis of 4894 patients from 24 randomized double\u2010blind placebo\u2010controlled clinical trials. J. Am. Heart Assoc. 5, e003896 (2016).","journal-title":"J. Am. Heart Assoc."},{"key":"934_CR128","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","volume":"393","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink, H. J. L. et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393, 1937\u20131947 (2019).","journal-title":"Lancet"},{"key":"934_CR129","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin, B. H. et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 402, 2077\u20132090 (2023).","journal-title":"Lancet"},{"key":"934_CR130","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","volume":"389","author":"MN Rheault","year":"2023","unstructured":"Rheault, M. N. et al. Sparsentan versus irbesartan in focal segmental glomerulosclerosis. N. Engl. J. Med. 389, 2436\u20132445 (2023).","journal-title":"N. Engl. J. Med."},{"key":"934_CR131","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","volume":"402","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet 402, 2004\u20132017 (2023).","journal-title":"Lancet"},{"key":"934_CR132","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295\u20132306 (2019).","journal-title":"N. Engl. J. Med."},{"key":"934_CR133","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"key":"934_CR134","doi-asserted-by":"crossref","unstructured":"Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 388, 117\u2013127 (2023).","DOI":"10.1056\/NEJMoa2204233"},{"key":"934_CR135","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M. & Cherney, D. Z. I. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134, 752\u2013772 (2016).","journal-title":"Circulation"},{"key":"934_CR136","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/ph17030362","volume":"17","author":"G Castoldi","year":"2024","unstructured":"Castoldi, G. et al. Sodium glucose cotransporter-2 inhibitors in non-diabetic kidney disease: evidence in experimental models. Pharmaceuticals 17, 362 (2024).","journal-title":"Pharmaceuticals"},{"key":"934_CR137","doi-asserted-by":"publisher","first-page":"C661","DOI":"10.1152\/ajpcell.00177.2023","volume":"325","author":"X Chen","year":"2023","unstructured":"Chen, X., Hocher, C.-F., Shen, L., Kr\u00e4mer, B. K. & Hocher, B. Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench. Am. J. Physiol. Cell Physiol. 325, C661\u2013C681 (2023).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"934_CR138","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.123.065517","volume":"149","author":"AM Billing","year":"2024","unstructured":"Billing, A. M. et al. Metabolic communication by SGLT2 inhibition. Circulation 149, 860\u2013884 (2024).","journal-title":"Circulation"},{"key":"934_CR139","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1056\/NEJMra1700312","volume":"377","author":"K Kalantar-Zadeh","year":"2017","unstructured":"Kalantar-Zadeh, K. & Fouque, D. Nutritional management of chronic kidney disease. N. Engl. J. Med. 377, 1765\u20131776 (2017).","journal-title":"N. Engl. J. Med."},{"key":"934_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98718-x","volume":"11","author":"C Barba","year":"2021","unstructured":"Barba, C. et al. A low aromatic amino-acid diet improves renal function and prevent kidney fibrosis in mice with chronic kidney disease. Sci. Rep. 11, 19184 (2021).","journal-title":"Sci. Rep."},{"key":"934_CR141","first-page":"CD001892","volume":"10","author":"D Hahn","year":"2020","unstructured":"Hahn, D., Hodson, E. M. & Fouque, D. Low protein diets for non-diabetic adults with chronic kidney disease. Cochrane Database Syst. Rev. 10, CD001892 (2020).","journal-title":"Cochrane Database Syst. Rev."},{"key":"934_CR142","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ajkd.2020.07.011","volume":"77","author":"AH Anderson","year":"2021","unstructured":"Anderson, A. H. et al. Novel risk factors for progression of diabetic and nondiabetic CKD: findings from the chronic renal insufficiency cohort (CRIC) study. Am. J. Kidney Dis. 77, 56\u201373.e1 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"934_CR143","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ekir.2020.12.019","volume":"6","author":"S Hultin","year":"2021","unstructured":"Hultin, S. et al. A systematic review and meta-analysis on effects of bicarbonate therapy on kidney outcomes. Kidney Int. Rep. 6, 695\u2013705 (2021).","journal-title":"Kidney Int. Rep."},{"key":"934_CR144","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.kint.2023.03.037","volume":"104","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials. Kidney Int. 104, 181\u2013188 (2023).","journal-title":"Kidney Int."},{"key":"934_CR145","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1681\/ASN.0000000000000243","volume":"34","author":"HL Heerspink","year":"2023","unstructured":"Heerspink, H. L. et al. Development and validation of a new hierarchical composite end point for clinical trials of kidney disease progression. J. Am. Soc. Nephrol. 34, 2025\u20132038 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"934_CR146","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","volume":"29","author":"LA Inker","year":"2023","unstructured":"Inker, L. A. et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat. Med. 29, 1867\u20131876 (2023).","journal-title":"Nat. Med."},{"key":"934_CR147","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.3390\/ijms25073678","volume":"25","author":"H Rupprecht","year":"2024","unstructured":"Rupprecht, H. et al. Assessment and risk prediction of chronic kidney disease and kidney fibrosis using non-invasive biomarkers. Int. J. Mol. Sci. 25, 3678 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"934_CR148","first-page":"1510","volume":"32","author":"C Pontillo","year":"2017","unstructured":"Pontillo, C. et al. A urinary proteome-based classifier for the early detection of decline in glomerular filtration. Nephrol. Dial. Transplant. 32, 1510\u20131516 (2017).","journal-title":"Nephrol. Dial. Transplant."},{"key":"934_CR149","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-8587(20)30026-7","volume":"8","author":"N Tofte","year":"2020","unstructured":"Tofte, N. et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 8, 301\u2013312 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"934_CR150","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.kint.2021.12.014","volume":"101","author":"L Berchtold","year":"2022","unstructured":"Berchtold, L. et al. Diffusion-magnetic resonance imaging predicts decline of kidney function in chronic kidney disease and in patients with a kidney allograft. Kidney Int. 101, 804\u2013813 (2022).","journal-title":"Kidney Int."},{"key":"934_CR151","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1159\/000536232","volume":"55","author":"D Zhao","year":"2024","unstructured":"Zhao, D. et al. Amide proton transfer-weighted magnetic resonance imaging for application in renal fibrosis: a radiological-pathological based analysis. Am. J. Nephrol. 55, 334\u2013344 (2024).","journal-title":"Am. J. Nephrol."},{"key":"934_CR152","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/bjr\/tqad030","volume":"97","author":"Z Chen","year":"2024","unstructured":"Chen, Z. et al. Association of renal elasticity evaluated by real-time shear wave elastography with renal fibrosis in patients with chronic kidney disease. Br. J. Radiol. 97, 392\u2013398 (2024).","journal-title":"Br. J. Radiol."},{"key":"934_CR153","doi-asserted-by":"publisher","first-page":"7385","DOI":"10.3390\/jcm12237385","volume":"12","author":"N Mancianti","year":"2023","unstructured":"Mancianti, N. et al. Using renal elastography to predict the therapeutic response of nephrological patients. J. Clin. Med. 12, 7385 (2023).","journal-title":"J. Clin. Med."},{"key":"934_CR154","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/RLI.0000000000001061","volume":"59","author":"S Bodard","year":"2024","unstructured":"Bodard, S. et al. Visualization of renal glomeruli in human native kidneys with sensing ultrasound localization microscopy. Invest. Radiol. 59, 561\u2013568 (2024).","journal-title":"Invest. Radiol."},{"key":"934_CR155","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.kint.2023.01.027","volume":"103","author":"S Bodard","year":"2023","unstructured":"Bodard, S. et al. Ultrasound localization microscopy of the human kidney allograft on a clinical ultrasound scanner. Kidney Int. 103, 930\u2013935 (2023).","journal-title":"Kidney Int."},{"key":"934_CR156","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.kint.2019.08.029","volume":"97","author":"M Baues","year":"2020","unstructured":"Baues, M. et al. Collagen-specific molecular imaging of renal fibrosis. Kidney Int. 97, 609\u2013614 (2020).","journal-title":"Kidney Int."},{"key":"934_CR157","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2967\/jnumed.122.264530","volume":"64","author":"D Izquierdo-Garcia","year":"2023","unstructured":"Izquierdo-Garcia, D. et al. Biodistribution, dosimetry, and pharmacokinetics of 68Ga-CBP8: a type I collagen-targeted PET probe. J. Nucl. Med. Publ. Soc. Nucl. Med. 64, 775\u2013781 (2023).","journal-title":"J. Nucl. Med. Publ. Soc. Nucl. Med."},{"key":"934_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41536-024-00348-0","volume":"9","author":"C Ji","year":"2024","unstructured":"Ji, C. et al. Engineered extracellular vesicle-encapsulated CHIP as novel nanotherapeutics for treatment of renal fibrosis. NPJ Regen. Med. 9, 1\u201311 (2024).","journal-title":"NPJ Regen. Med."},{"key":"934_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-49271-2","volume":"13","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y., Bi, D., Saunders, M. & Ji, Y. Prediction of chronic kidney disease progression using recurrent neural network and electronic health records. Sci. Rep. 13, 22091 (2023).","journal-title":"Sci. Rep."},{"key":"934_CR160","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052138","volume":"11","author":"O Aubert","year":"2021","unstructured":"Aubert, O. et al. Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. BMJ Open. 11, e052138 (2021).","journal-title":"BMJ Open."},{"key":"934_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36352-z","volume":"14","author":"S Crotta","year":"2023","unstructured":"Crotta, S. et al. Repair of airway epithelia requires metabolic rewiring towards fatty acid oxidation. Nat. Commun. 14, 721 (2023).","journal-title":"Nat. Commun."},{"key":"934_CR162","doi-asserted-by":"publisher","first-page":"tkad047","DOI":"10.1093\/burnst\/tkad047","volume":"12","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Metabolic reprogramming in skin wound healing. Burn. Trauma. 12, tkad047 (2024).","journal-title":"Burn. Trauma."},{"key":"934_CR163","doi-asserted-by":"publisher","first-page":"5497346","DOI":"10.1155\/2021\/5497346","volume":"2021","author":"Y Li","year":"2021","unstructured":"Li, Y., Sha, Z. & Peng, H. Metabolic reprogramming in kidney diseases: evidence and therapeutic opportunities. Int. J. Nephrol. 2021, 5497346 (2021).","journal-title":"Int. J. Nephrol."},{"key":"934_CR164","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1007\/s00535-013-0766-5","volume":"48","author":"K Tokushige","year":"2013","unstructured":"Tokushige, K. et al. Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease. J. Gastroenterol. 48, 1392\u20131400 (2013).","journal-title":"J. Gastroenterol."},{"key":"934_CR165","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cca.2013.03.033","volume":"422","author":"Y-Y Zhao","year":"2013","unstructured":"Zhao, Y.-Y. Metabolomics in chronic kidney disease. Clin. Chim. Acta 422, 59\u201369 (2013).","journal-title":"Clin. Chim. Acta"},{"key":"934_CR166","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1021\/acs.jproteome.6b00156","volume":"15","author":"YP Kang","year":"2016","unstructured":"Kang, Y. P. et al. Metabolic profiling regarding pathogenesis of idiopathic pulmonary fibrosis. J. Proteome Res. 15, 1717\u20131724 (2016).","journal-title":"J. Proteome Res."},{"key":"934_CR167","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41581-024-00889-z","volume":"21","author":"V Miguel","year":"2024","unstructured":"Miguel, V., Shaw, I. W. & Kramann, R. Metabolism at the crossroads of inflammation and fibrosis in chronic kidney disease. Nat. Rev. Nephrol. 21, 39\u201356 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"934_CR168","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1681\/ASN.2017030350","volume":"29","author":"F Afshinnia","year":"2018","unstructured":"Afshinnia, F. et al. Impaired \u03b2-oxidation and altered complex lipid fatty acid partitioning with advancing CKD. J. Am. Soc. Nephrol. 29, 295 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"934_CR169","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41581-023-00741-w","volume":"19","author":"A Mitrofanova","year":"2023","unstructured":"Mitrofanova, A., Merscher, S. & Fornoni, A. Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease. Nat. Rev. Nephrol. 19, 629\u2013645 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"934_CR170","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1164\/rccm.201504-0780OC","volume":"192","author":"N Xie","year":"2015","unstructured":"Xie, N. et al. Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis. Am. J. Respir. Crit. Care Med. 192, 1462\u20131474 (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"934_CR171","doi-asserted-by":"publisher","first-page":"F561","DOI":"10.1152\/ajprenal.00036.2017","volume":"313","author":"H Ding","year":"2017","unstructured":"Ding, H. et al. Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis. Am. J. Physiol. Renal Physiol. 313, F561\u2013F575 (2017).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"934_CR172","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/gutjnl-2023-330962","volume":"73","author":"A Wester","year":"2024","unstructured":"Wester, A., Shang, Y., Toresson Grip, E., Matthews, A. A. & Hagstr\u00f6m, H. Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes. Gut 73, 835\u2013843 (2024).","journal-title":"Gut"},{"key":"934_CR173","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s42255-018-0008-5","volume":"1","author":"X Zhao","year":"2019","unstructured":"Zhao, X. et al. Metabolic regulation of dermal fibroblasts contributes to skin extracellular matrix homeostasis and fibrosis. Nat. Metab. 1, 147\u2013157 (2019).","journal-title":"Nat. Metab."},{"key":"934_CR174","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1124\/jpet.121.000811","volume":"379","author":"RN Willette","year":"2021","unstructured":"Willette, R. N. et al. Modulation of oxidative phosphorylation with IM156 attenuates mitochondrial metabolic reprogramming and inhibits pulmonary fibrosis. J. Pharmacol. Exp. Ther. 379, 290\u2013300 (2021).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"934_CR175","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1007\/s13346-023-01362-3","volume":"13","author":"DM Dogbey","year":"2023","unstructured":"Dogbey, D. M. et al. Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy. Drug. Deliv. Transl. Res. 13, 2719\u20132738 (2023).","journal-title":"Drug. Deliv. Transl. Res."},{"key":"934_CR176","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.arabjc.2017.05.011","volume":"12","author":"I Khan","year":"2019","unstructured":"Khan, I., Saeed, K. & Khan, I. Nanoparticles: properties, applications and toxicities. Arab. J. Chem. 12, 908\u2013931 (2019).","journal-title":"Arab. J. Chem."},{"key":"934_CR177","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12951-022-01477-8","volume":"20","author":"N Joudeh","year":"2022","unstructured":"Joudeh, N. & Linke, D. Nanoparticle classification, physicochemical properties, characterization, and applications: a comprehensive review for biologists. J. Nanobiotechnol. 20, 262 (2022).","journal-title":"J. Nanobiotechnol."},{"key":"934_CR178","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.nantod.2017.03.001","volume":"15","author":"SM Moghimi","year":"2017","unstructured":"Moghimi, S. M. & Simberg, D. Complement activation turnover on surfaces of nanoparticles. Nano Today 15, 8\u201310 (2017).","journal-title":"Nano Today"},{"key":"934_CR179","doi-asserted-by":"crossref","unstructured":"Suriya Prabha, A. et al. in Nanotoxicity (eds Rajendran, S. et al.) Ch. 7, 143\u2013165 (Elsevier, 2020).","DOI":"10.1016\/B978-0-12-819943-5.00007-5"},{"key":"934_CR180","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ces.2014.06.042","volume":"125","author":"BK Lee","year":"2015","unstructured":"Lee, B. K., Yun, Y. H. & Park, K. Smart nanoparticles for drug delivery: boundaries and opportunities. Chem. Eng. Sci. 125, 158\u2013164 (2015).","journal-title":"Chem. Eng. Sci."},{"key":"934_CR181","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun, L. et al. Smart nanoparticles for cancer therapy. Signal. Transduct. Target. Ther. 8, 1\u201328 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"934_CR182","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1039\/b505099e","volume":"15","author":"A Perro","year":"2005","unstructured":"Perro, A., Reculusa, S., Ravaine, S., Bourgeat-Lami, E. & Duguet, E. Design and synthesis of Janus micro- and nanoparticles. J. Mater. Chem. 15, 3745\u20133760 (2005).","journal-title":"J. Mater. Chem."},{"key":"934_CR183","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1021\/cr300089t","volume":"113","author":"A Walther","year":"2013","unstructured":"Walther, A. & M\u00fcller, A. H. E. Janus particles: synthesis, self-assembly, physical properties, and applications. Chem. Rev. 113, 5194\u20135261 (2013).","journal-title":"Chem. Rev."},{"key":"934_CR184","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/all.12357","volume":"69","author":"P Torregrosa Paredes","year":"2014","unstructured":"Torregrosa Paredes, P. et al. Differences in exosome populations in human breast milk in relation to allergic sensitization and lifestyle. Allergy 69, 463\u2013471 (2014).","journal-title":"Allergy"},{"key":"934_CR185","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/biosci\/biv084","volume":"65","author":"MP Zaborowski","year":"2015","unstructured":"Zaborowski, M. P., Balaj, L., Breakefield, X. O. & Lai, C. P. Extracellular vesicles: composition, biological relevance, and methods of study. Bioscience 65, 783\u2013797 (2015).","journal-title":"Bioscience"},{"key":"934_CR186","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri3622","volume":"14","author":"PD Robbins","year":"2014","unstructured":"Robbins, P. D. & Morelli, A. E. Regulation of immune responses by extracellular vesicles. Nat. Rev. Immunol. 14, 195\u2013208 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"934_CR187","doi-asserted-by":"publisher","first-page":"113775","DOI":"10.1016\/j.addr.2021.04.013","volume":"175","author":"A Nagelkerke","year":"2021","unstructured":"Nagelkerke, A. et al. Extracellular vesicles for tissue repair and regeneration: evidence, challenges and opportunities. Adv. Drug. Deliv. Rev. 175, 113775 (2021).","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"934_CR188","doi-asserted-by":"publisher","first-page":"27066","DOI":"10.3402\/jev.v4.27066","volume":"4","author":"M Y\u00e1\u00f1ez-M\u00f3","year":"2015","unstructured":"Y\u00e1\u00f1ez-M\u00f3, M. et al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles 4, 27066 (2015).","journal-title":"J. Extracell. Vesicles"},{"key":"934_CR189","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087853","volume":"9","author":"HY Choi","year":"2014","unstructured":"Choi, H. Y. et al. Microparticles from kidney-derived mesenchymal stem cells act as carriers of proangiogenic signals and contribute to recovery from acute kidney injury. PLoS ONE 9, e87853 (2014).","journal-title":"PLoS ONE"},{"key":"934_CR190","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fcell.2020.00188","volume":"8","author":"S Kholia","year":"2020","unstructured":"Kholia, S. et al. Mesenchymal stem cell derived extracellular vesicles ameliorate kidney injury in aristolochic acid nephropathy. Front. Cell Dev. Biol. 8, 188 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"934_CR191","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13287-020-01767-8","volume":"11","author":"Z Shi","year":"2020","unstructured":"Shi, Z., Wang, Q., Zhang, Y. & Jiang, D. Extracellular vesicles produced by bone marrow mesenchymal stem cells attenuate renal fibrosis, in part by inhibiting the RhoA\/ROCK pathway, in a UUO rat model. Stem Cell Res. Ther. 11, 253 (2020).","journal-title":"Stem Cell Res. Ther."},{"key":"934_CR192","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41100-9","volume":"9","author":"C Grange","year":"2019","unstructured":"Grange, C. et al. Stem cell-derived extracellular vesicles inhibit and revert fibrosis progression in a mouse model of diabetic nephropathy. Sci. Rep. 9, 4468 (2019).","journal-title":"Sci. Rep."},{"key":"934_CR193","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-016-0068-0","volume":"20","author":"W Nassar","year":"2016","unstructured":"Nassar, W. et al. Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases. Biomater. Res. 20, 21 (2016).","journal-title":"Biomater. Res."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-00934-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-00934-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-00934-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T08:02:03Z","timestamp":1745308923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-00934-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":193,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1038\/s41581-025-00934-5","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"20 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}